Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A UC Berkeley-developed compound called TOFA could reshape obesity treatment by boosting the body's energy burn rather than just curbing appetite. In mice, it cut fat, preserved muscle, and improved blood sugar — without raising body temperature or activity levels. Even better, it made GLP-1 drugs like Ozempic and Wegovy work more effectively when combined.
Researchers at UC Berkeley have identified an experimental compound called TOFA (5-tetradecyloxy-2-furoic acid) that takes a fundamentally different approach to weight loss: instead of suppressing appetite like GLP-1 drugs (think Ozempic and Wegovy), it ramps up how much energy the body burns. In obese mice, TOFA improved insulin sensitivity, reduced liver fat, lowered triglycerides, and drove fat loss — all while preserving lean muscle mass, a major drawback of current obesity medications.
What makes TOFA stand out is its dual mechanism. It blocks fatty acid production (as an ACC inhibitor) while simultaneously activating fat-burning receptors (PPARα and PPARδ), creating a coordinated metabolic response that single-mechanism compounds can't replicate. When combined with semaglutide or tirzepatide, the results were even stronger than either treatment alone — suggesting TOFA could complement, not replace, existing GLP-1 therapies.
By the Numbers
Why it matters: Muscle loss is one of the biggest concerns with current weight-loss drugs, and no ACC inhibitor has yet been approved for metabolic disease. If TOFA's results translate to humans, it could offer a powerful new tool — alone or alongside GLP-1s — for tackling obesity, diabetes, and fatty liver disease.